pharmaphorum

DECEMBER 21, 2020

Their technology is based on synthetic messenger RNA – short for ribose nucleic acid – which is a short transcript of a longer DNA code. As it’s just a messenger molecule, it does not affect the body’s own genetic code when it is injected as a vaccine – but what it does do is instruct cells to code for copies of a certain protein.

Vaccination 111

Vaccination Vaccine Doctors Doctor 111

XTalks

DECEMBER 13, 2023

These companies were identified through The Americas’ Fastest-Growing Companies 2023 list by the Financial Times. Another noteworthy product, Patient Pure (PPX), is the first of its kind, a concentrated autologous exosome solution containing nanoparticles and proteins extracted from a patient’s own blood. million and $38.8

Genetics 111

Genetics Vaccination Vaccine DNA 111

pharmaphorum

NOVEMBER 23, 2021

The bolt-on deal comes – which includes an upfront payment of $120 million and up to $910 million in milestones – covers rights to ARO-HSD, Arrowhead’s RNA interference drug targeting an enzyme called HSD17B13 that seems to contribute to the pathology of NASH and other liver diseases.

Sales 52

Sales Drugs Trials RNA 52

Delveinsight

AUGUST 6, 2020

Transthyretin (TTR) is a protein that the liver produces to facilitate the transfer of thyroid hormone and vitamin A in the blood. However, due to specific reasons, the TTR protein begins to misfold and aggregate as fibrils, a process known as amyloidosis of Transthyretin (ATTR). Liver Transplantation.

Gene Silencing 52

Gene Silencing Protein Marketing Gene 52

Drug Discovery World

SEPTEMBER 28, 2022

Its application in pharma, most commonly in drug discovery, has been steadily growing with global partnerships between tech vendors and pharma companies becoming more commonplace. Biotech and AI companies founded by purely tech professionals often opt to bring in pharma executives with insider knowledge further down the line.

Pharma Companies 52

Pharma Companies Drugs In-Vivo Genetics 52

pharmaphorum

JANUARY 10, 2022

The pandemic brought about an interesting phenomenon for the pharmaceutical industry: there is a much greater awareness of both individual companies within the industry and their individual treatments. Prior to the pandemic, biotech had a market cap of around $6.5bn whereas, at present, it is now valued at approximately $144bn.

RNA 111

RNA Vaccination Vaccine Pharma Companies 111

Delveinsight

FEBRUARY 8, 2021

The major factors shaping the market outlook include prevalence, monopoly of a pharma company, diagnostics and screening methodologies, entry of other market players in the Cystic Fibrosis market domain, as well as restraints. and Verona Pharma’s RPL 554.

Marketing 52

Marketing Production Development RNA 52

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

Drug Discovery World

OCTOBER 4, 2022

As it stands, there are currently 19 gene therapies approved for clinical use, alongside 18 RNA therapies and 59 non-genetically modified cell therapies, according to the Q2 report by the American Society of Cell & Gene Therapy. This year has seen some major deals announced by big pharma companies.

Gene Therapy 52

Gene Therapy Drugs Gene Manufacturing 52

pharmaphorum

DECEMBER 7, 2021

The deal – which is weighted heavily towards neuroscience with just one cancer programme covered – is the second between Recursion and a big pharma company in the space of two days, coming on the heels of a smaller alliance with Bayer that will look for new fibrosis drugs.

Drugs 59

Drugs RNA Pharma Companies Protein 59

pharmaphorum

MARCH 11, 2022

However, the financial success that has been delivered to certain companies working on vaccine development has emerged after a long period where investing in the space had become increasingly unpopular among the larger pharma companies.

Vaccination 81

Vaccination Vaccine Development Manufacturing 81

pharmaphorum

AUGUST 23, 2022

Explaining why Ampligen may prove effective, the spokesperson said, “Ampligen is a selective TLR3 agonist which — to put it very simply — works to activate immune cells, shut down protein replication and chew-up viral RNA, all of which can help stop the virus from replicating and hopefully even eradicate it.

Vaccination 134

Vaccination Vaccine Development Trials 134